Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — FY2024 Earnings Presentation

40 slides from Neurocrine Biosciences's earnings presentation, Feb 6, 2025

  1. Slide 1: Q4 and Year-End 2024 Earnings Presentation

    Advancing Life-Changing Discoveries in Neuroscience Neurocrine Biosciences (Nasdaq: NBIX) Q4 and Year-End 2024 Earnings Presentation February 6, 2025

  2. Slide 2: Safe Harbor and Forward-Looking Statements

    Safe Harbor and Forward-Looking Statements In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our products an

  3. Slide 3: Where Are We Today?

    Where Are We Today? Neurocrine Discovered / Developed Discovered and Developed Four Novel FDA-Approved Programs In the U.S. Deep Expertise in Neuroscience Drug Development * Fully-Integrated Organization with R&D and Commercial Capabilities Growing Blockbuster Commercial Product in INGREZZA with Str

  4. Slide 4: Well-Positioned for Sustained & Long-Term Growth

    Well-Positioned for Sustained & Long-Term Growth COMMERCIAL* RESEARCH & DEVELOPMENT STRONG FINANCIAL POSITION • Neurology $2.50 - $2.60 Billion • Neuroendocrinology Therapeutic 2025 INGREZZA Area Annual Net Sales Guidance • Neuropsychiatry TARDIVE DYSKINESIA AND Diversification HUNTINGTON’S DISEASE

  5. Slide 5: Our Pipeline Today – 12 Programs

    Modality Key Our Pipeline Today – 12 Programs Small Molecule PROGRAM (TARGET) MODALITY THERAPEUTIC AREA INDICATION PHASE 1 PHASE 2 PHASE 3 valbenazine (VMAT2 Inhibitor) Neuropsychiatry Adjunctive Treatment of Schizophrenia valbenazine (VMAT2 Inhibitor) Neurology Dyskinetic Cerebral Palsy Inadequate

  6. Slide 6: 2024 Highlights and 2025 Key Milestones and Activities

    2024 Highlights and 2025 Key Milestones and Activities 2024 Highlights 2025 Key Milestones and Activities ▪ INGREZZA® (valbenazine) Net Product Sales of ~$2.31B in 2024 ▪ Deliver on INGREZZA Net Sales Guidance of $2.5 - $2.6B − Represents ~$480 Million YoY Sales Growth, or 26% vs. 2023 ▪ Successfull

  7. Slide 7: 2024 Financial Summary

    2024 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item 2024 2023 Highlights / Comments Revenue $2,355 $1,887 2024 INGREZZA Sales of ~$2.3B Represents YoY Growth of - Product Sales, Net $2,331 $1,861 26% vs. FY 2023 - Collaboration Revenue $25 $27 Increase Due to Support Expanded

  8. Slide 8: Q4 2024 Financial Summary

    Q4 2024 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item Q4 2024 Q4 2023 Highlights / Comments Revenue $628 $515 INGREZZA Sales of $615M Represents YoY Growth of 23% - Product Sales, Net $621 $507 Driven by Strong Underlying Patient Demand and Improvement in Gross-to-Net Dynamic

  9. Slide 9: 2025 INGREZZA Net Sales and Expense Guidance

    2025 INGREZZA Net Sales and Expense Guidance Item ($ Millions) 2024 Actuals 2025 Guidance Range INGREZZA Net Product Sales1 $2,314 $2,500 - $2,600 GAAP R&D Expense2 $731 $960 - $1,010 Non-GAAP R&D Expense2, 3 $662 $890 - $940 GAAP SG&A Expense4 $1,007 $1,110 - $1,130 Non-GAAP SG&A Expense3, 4 $863 $

  10. Slide 10: Corporate Sustainability: "A" Rating at MSCI

    Corporate Sustainability: “A” Rating at MSCI and Rank in 11th Percentile for Biotech at Sustainalytics Our Purpose: Relieve Suffering for People with Great Needs Adhere to the highest Invest in our people Minimize our impact product quality and and communities on the environment safety standards Com

  11. Slide 11: Our Medicines, Our Patients

    © NEYROCRINE | Our Medicines, Our Patients

  12. Slide 12: INGREZZA (valbenazine) capsules

    NEUROGRINE INGREZZA (valbenazine) capsules

  13. Slide 13: INGREZZA Quarterly Net Sales Performance

    INGREZZA Quarterly Net Sales Performance ($Million) Q4 2024 Sales of $615M Represents $650 23% Year-Over-Year Growth vs. Q4 2023 $613 $615 $600 $580 $550 $500 $506 $500 $486 $450 $440 $410 $400 $350 Q1 '23 Q2 '23 Q3 '23 Q4 '23 Q1 '24 Q2 '24 Q3 '24 Q4 '24 13

  14. Slide 14: Substantial Impact on TD Patients and Care Partners

    Substantial Impact on TD Patients and Care Partners Movement disorder caused by prolonged use of antipsychotics and anti-nausea medications Uncontrollable, abnormal and repetitive movements >50% of patients experience meaningful emotional, social and psychological impact* Job Performance Low Self-Wo

  15. Slide 15: Nascent Tardive Dyskinesia Market Presents Significant Opportunity

    Nascent Tardive Dyskinesia Market Presents Significant Opportunity ESTIMATED TO AFFECT ~800,000 Nearly 9 of 10 TD PATIENTS ARE NOT CURRENTLY people in the U.S. TREATED WITH A VMAT2 INHIBITOR LIKE INGREZZA Source: U.S.Claims Data and 31 Global Scientific Publications; U.S. Tardive Dyskinesia Prevalen

  16. Slide 16: INGREZZA Approved by the FDA for Chorea Associated with Huntington's Disease

    INGREZZA® Approved by the FDA for the Treatment of Chorea Associated with Huntington’s Disease INGREZZA Simple once-a-day treatment targeted for symptom control of chorea movements Safety profile consistent with and supported by extensive safety data in tardive dyskinesia In randomized, double-blind

  17. Slide 17: CRENESSITY

    mn yd Crenessity™ PeNeoolty NEUROCRINE’ BIOSCIENCES

  18. Slide 18: CRENESSITY Offers Potential to Change Standard of Care

    CRENESSITY Offers Potential to Change Standard of Care First New Treatment Available for Classic CAH in 70 Years ABOUT CRENESSITY ABOUT CAH • First medication approved as an adjunct treatment to • Rare and lifelong genetic condition that affects glucocorticoid replacement to control androgens in app

  19. Slide 19: Neuropsychiatry Pipeline

    (5) NEUROCRINE BIOSCIENCES

  20. Slide 20: Osavampator: Positive Phase 2 Top-Line Results in Major Depressive Disorder

    Osavampator* (AMPA Potentiator): Reported Positive Phase 2 Top- Line Study Results in Adults with Major Depressive Disorder Inadequate Response to Treatment osavampator (previously NBI-’845) in Major Depressive Disorder (MDD) Potent first-in-class AMPA potentiator ~1/3 of the 16 million+ people in t

  21. Slide 21: Osavampator SAVITRI Phase 2 Summary Results

    TM Osavampator* (AMPA Potentiator) SAVITRI Phase 2 Study Summary Results EFFICACY SAFETY AND TOLERABILITY • The study met its primary and key secondary endpoints • NBI-1065845 was generally well-tolerated • Once-daily, oral administration of NBI-’845 produced a • Most common adverse event was headac

  22. Slide 22: Muscarinic Platform Includes Multiple Clinical Programs

    Muscarinic Platform Includes Multiple Clinical Programs From M1 to M4 Selective Orthosteric Agonists M1 M1/M4 M4 “Cognition” DUAL “Psychosis” ▪ Phase 1 PREFERRING ▪ Advancing to Phase 2 in PREFERRING Schizophrenia in 2H 2025 ▪ Phase 1 ▪ Phase 1 NBI-’570 SELECTIVE NBI-’567 NBI-’569 SELECTIVE ▪ Comple

  23. Slide 23: Summary of NBI-'568 Positive Phase 2 Topline Results

    Summary of NBI-’568* Positive Phase 2 Topline Results Once-Daily 20mg Dose: Efficacy, Safety, and Tolerability Results Support Advancement to Phase 3 in 1H 2025 20mg Once-daily Demonstrated Efficacy, Safety and Tolerability Profile Statistically Significant and Clinically Generally Safe and Well-tol

  24. Slide 24: PANSS Total Score Change from Baseline

    Once-Daily 20mg Dose Demonstrated Clinically Meaningful and Statistically Significant Efficacy at Week 3, 4, 5, and 6 0 20mg QD Efficacy Data PANSS Total Score Change from Baseline LS Mean1 ± SEM -5.7 Week 4 – Week 6 -5 -8.2 -7.7 Week 4 5 6** -9.6 PANSS Total Score -8.4 -10.2 -10 -10.8 -11.5 LS Mean

  25. Slide 25: Statistically Significant Improvement in Additional Endpoints

    Once-Daily 20mg Dose Demonstrated Statistically Significant Improvement in Additional Endpoints \ CGI-S Marder Factor — Positive Marder Factor — Negative Placebo 20mg QD Placebo 20mg QD Placebo 20mg QD Week 6 N=68 N=35 N=68 N=35 N=68 N=35 LS Mean Change from Baseline* -0.5 -1.2 -2.8 -5.8 -1.2 -3.1 L

  26. Slide 26: NBI-'568 Was Generally Safe and Well Tolerated at All Doses Studied

    NBI-’568 Was Generally Safe and Well Tolerated at All Doses Studied Treatment-Emergent Adverse Events Occurring in ≥ 5% of NBI-'568 All Treated Group Placebo 20mg QD 40mg QD 60mg QD 30mg BID All Treated \ N=70 N=40 N=39 N=34 N=27 N=140 Somnolence 2 (2.9) 5 (12.5) 2 (5.1) 7 (20.6) 1 (3.7) 15 (10.7) D

  27. Slide 27: NBI-'568 is the First and Only Muscarinic M4 Selective Orthosteric Agonist

    NBI-’568 is the First and Only Muscarinic M4 Selective Orthosteric Agonist in Clinical Development Type of Large Opportunity For NBI-'568, A Novel And Subtype Requires Endogenous Muscarinic Differentiated Asset Selectivity Ligand (Acetylcholine) Activation With no reliance on innate acetylcholine le

  28. Slide 28: NBI-'568 Effect Size Comparable to Known Muscarinic Programs

    NBI-’568 Effect Size Comparable to Known Muscarinic Programs and Leading Antipsychotics Clinical-Stage Muscarinic Programs Leading Approved Treatments 0.75 0.68 0.61 0.61 0.60 Effect Size 0.56 0.55 0.42 0.41 0.36 0.34 0.3 0.26 125mg / 30mg 30mg QD 125mg / 30mg 20mg 125mg / 30mg Zyprexa Risperdal Ser

  29. Slide 29: Valbenazine Phase 3 Study for Adjunctive Treatment of Schizophrenia

    Valbenazine*: Phase 3 Study for the Adjunctive Treatment of Schizophrenia with Top-Line Data in 2025 Adjunctive Treatment of Schizophrenia (ATS) Schizophrenia is one of the leading causes of disability worldwide, affecting up to 3.5M people in the U.S. alone. A serious, chronic mental illness that c

  30. Slide 30: Neurology Pipeline

    © NEVROGRINE Neurology Pipeline

  31. Slide 31: Neurology Programs in Clinical Development

    Neurology Programs in Clinical Development Valbenazine* Valbenazine in ATS NBI-’890* RESEARCH & DEVELOPMENT NBI-’355* POSITION STRONG FINANCIAL • VMAT2 Inhibitor • Next Generation VMAT2 Inhibitor • Selective Nav1.2 / Nav1.6 Inhibitor • Ongoing Phase 3 Study in Dyskinetic ✓ High Potency / Low Solubil

  32. Slide 32: R&D Will Deliver A New Medicine Every Two Years

    R&D Will Deliver A New Medicine Every Two Years Multimodality Mid-stage pipeline focused on clinically Commitment to R&D innovation engine or genetically validated targets R&D Sustainability Research 4+ Phase 1 Starts Target level of productivity each year 2+ Phase 2 Starts (On Average) 3+ Phase 3 P

  33. Slide 33: Our Pipeline Tomorrow – 18 Programs

    Modality Key Small Molecule Peptide Antibody Gene Therapy Our Pipeline Tomorrow – 18 Programs Study Status Key End of 2025 Current Study Study Initiating PROGRAM (TARGET) MO D A L I T Y THERAPEUTIC AREA INDICAT I ON PHASE 1 PHASE 2 PHASE 3 valbenazine (VMAT2 Inhibitor) Neuropsychiatry Adjunctive Tre

  34. Slide 34: Well-Positioned for Sustained & Long-Term Growth

    Well-Positioned for Sustained & Long-Term Growth COMMERCIAL* RESEARCH & DEVELOPMENT STRONG FINANCIAL POSITION • Neurology $2.50 - $2.60 Billion • Neuroendocrinology Therapeutic 2025 INGREZZA Area Annual Net Sales Guidance • Neuropsychiatry TARDIVE DYSKINESIA AND Diversification HUNTINGTON’S DISEASE

  35. Slide 35: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations

  36. Slide 36: Condensed Consolidated Statements of Income

    NEUROCRINE’ BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (in millions, except per share data) Revenues: Net product sales Collaboration revenue Total revenues Operating expenses: Cost of revenues Research and development Acquired in-process research and develo

  37. Slide 37: Condensed Consolidated Balance Sheets

    NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) December 31, December 31, (in millions) 2024 2023 Cash, cash equivalents, and marketable securities $ 1,076.1 $ 1,031.6 Other current assets 648.6 575.4 Total current assets 1,724.7 1,607.0 Deferred tax assets 485.7 362.6

  38. Slide 38: Reconciliation of GAAP to Non-GAAP Financial Results

    NEUROCRINE’ BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS, (unaudited) Three Months Ended ‘Twelve Months Ended December 31, December 31, (in millions, except per share data) 2024 2023 2024 2023 GAAP net income ! $ 103.1 $ 147.7 $ 3413 $ 249.7 Adjustmen

  39. Slide 39: Reconciliation of GAAP to Non-GAAP Expenses

    NEUROCRINE’ BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP EXPENSES (unaudited) (n mitions) GAAP cost of revenues Adjustments: Non-cash amortization related to acquired intangible assets ‘Non-GAAP cost of revenues (in miions) GAAP R&D Adjustments Stock-based compensation

  40. Slide 40: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Neurocrine Biosciences (Nasdaq: NBIX) Q4 and Year-End 2024 Earnings Presentation February 6, 2025

Neurocrine Biosciences — FY2024 Earnings Presentation on 6ix